BACKGROUND: Grade-III invasive ductal carcinomas of no special type (IDCs-NST) constitute a heterogeneous group of tumours with different clinical behaviour and response to chemotherapy. As many as 25% of all grade-III IDCs-NST are known to harbour a basal-like phenotype, as defined by gene expression profiling or immunohistochemistry for basal cytokeratins. Patients with basal-like breast carcinomas (BLBC) are reported to have a shorter disease-free and overall survival. MATERIAL AND METHODS: A retrospective analysis of 49 patients with BLBC (as defined by basal cytokeratin expression) and 49 controls matched for age, nodal status and grade was carried out. Histological features, immunohistochemical findings for oestrogen receptor (ER), progesterone receptor (PgR) and HER2, and clinical outcome and survival after adjuvant chemotherapy were compared between the two groups. RESULTS: It was more likely for patients with BLBCs to be found negative for ER (p<0.0001), PgR (p<0.0001) and HER2 (p<0.01) than controls. Patients with BLBCs were found to have a significantly higher recurrence rate (p<0.05) and were associated with significantly shorter disease-free and overall survival (both p<0.05). In the group of patients who received anthracycline-based adjuvant chemotherapy (BLBC group, n = 47; controls, n = 49), both disease-free and overall survival were found to be significantly shorter in the BLBC group (p<0.05). CONCLUSIONS: BLBCs are a distinct clinical and pathological entity, characterised by high nuclear grade, lack of hormone receptors and HER2 expression and a more aggressive clinical course. Standard adjuvant chemotherapy seems to be less effective in these tumours and new therapeutic approaches are indicated.
BACKGROUND: Grade-III invasive ductal carcinomas of no special type (IDCs-NST) constitute a heterogeneous group of tumours with different clinical behaviour and response to chemotherapy. As many as 25% of all grade-III IDCs-NST are known to harbour a basal-like phenotype, as defined by gene expression profiling or immunohistochemistry for basal cytokeratins. Patients with basal-like breast carcinomas (BLBC) are reported to have a shorter disease-free and overall survival. MATERIAL AND METHODS: A retrospective analysis of 49 patients with BLBC (as defined by basal cytokeratin expression) and 49 controls matched for age, nodal status and grade was carried out. Histological features, immunohistochemical findings for oestrogen receptor (ER), progesterone receptor (PgR) and HER2, and clinical outcome and survival after adjuvant chemotherapy were compared between the two groups. RESULTS: It was more likely for patients with BLBCs to be found negative for ER (p<0.0001), PgR (p<0.0001) and HER2 (p<0.01) than controls. Patients with BLBCs were found to have a significantly higher recurrence rate (p<0.05) and were associated with significantly shorter disease-free and overall survival (both p<0.05). In the group of patients who received anthracycline-based adjuvant chemotherapy (BLBC group, n = 47; controls, n = 49), both disease-free and overall survival were found to be significantly shorter in the BLBC group (p<0.05). CONCLUSIONS: BLBCs are a distinct clinical and pathological entity, characterised by high nuclear grade, lack of hormone receptors and HER2 expression and a more aggressive clinical course. Standard adjuvant chemotherapy seems to be less effective in these tumours and new therapeutic approaches are indicated.
Authors: Matt van de Rijn; Charles M Perou; Rob Tibshirani; Phillippe Haas; Olli Kallioniemi; Juha Kononen; Joachim Torhorst; Guido Sauter; Markus Zuber; Ossi R Köchli; Frank Mross; Holger Dieterich; Rob Seitz; Doug Ross; David Botstein; Pat Brown Journal: Am J Pathol Date: 2002-12 Impact factor: 4.307
Authors: T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: Christos Sotiriou; Soek-Ying Neo; Lisa M McShane; Edward L Korn; Philip M Long; Amir Jazaeri; Philippe Martiat; Steve B Fox; Adrian L Harris; Edison T Liu Journal: Proc Natl Acad Sci U S A Date: 2003-08-13 Impact factor: 11.205
Authors: Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein Journal: Proc Natl Acad Sci U S A Date: 2003-06-26 Impact factor: 12.779
Authors: Yiing Lin; Shin Lin; Mark Watson; Kathryn M Trinkaus; Sacha Kuo; Michael J Naughton; Katherine Weilbaecher; Timothy P Fleming; Rebecca L Aft Journal: Breast Cancer Res Treat Date: 2009-12-06 Impact factor: 4.872
Authors: Babette Siebold Saltzman; Kathleen E Malone; Jean A McDougall; Janet R Daling; Christopher I Li Journal: Breast Cancer Res Treat Date: 2012-08-19 Impact factor: 4.872
Authors: E Y Tan; M Yan; L Campo; C Han; E Takano; H Turley; I Candiloro; F Pezzella; K C Gatter; E K A Millar; S A O'Toole; C M McNeil; P Crea; D Segara; R L Sutherland; A L Harris; S B Fox Journal: Br J Cancer Date: 2009-01-27 Impact factor: 7.640
Authors: Silvia Darb-Esfahani; Sibylle Loibl; Berit M Müller; Marc Roller; Carsten Denkert; Martina Komor; Karsten Schlüns; Jens Uwe Blohmer; Jan Budczies; Bernd Gerber; Aurelia Noske; Andreas du Bois; Wilko Weichert; Christian Jackisch; Manfred Dietel; Klaus Richter; Manfred Kaufmann; Gunter von Minckwitz Journal: Breast Cancer Res Date: 2009 Impact factor: 6.466